Master10
Public Health, Nutrition & Epidemics20 Concepts & Facts

Pharmacovigilance & Drug Safety Monitoring GK Questions & Answers

Reviewed by the Master10 Editorial Board for accuracy, clarity and competitive-exam relevance.Editorial Policy
Pharmacovigilance is defined by the World Health Organization as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. While pharmaceutical compounds undergo rigorous pre-clinical testing and phased clinical trials before receiving marketing authorization, these preliminary evaluations involve restricted, homogeneous patient cohorts monitored over limited durations. Consequently, pre-market clinical evaluations rarely detect rare adverse events, late-onset chronic toxicities, drug-drug interactions, or adverse outcomes among vulnerable demographics such as pregnant women, elderly individuals, and pediatric patients. Pharmacovigilance provides ongoing safety surveillance throughout the entire commercial lifecycle of a pharmaceutical product.

The modern discipline of pharmacovigilance emerged largely in response to the thalidomide catastrophe of the late 1950s and early 1960s. Thalidomide, widely marketed across Europe and other continents as an anti-nausea remedy for morning sickness in pregnant mothers, caused severe congenital limb deformities known as phocomelia in more than ten thousand infants. This tragedy underscored the urgent necessity for rigorous post-marketing surveillance and independent drug regulatory standards worldwide. In 1968, the World Health Organization established the Programme for International Drug Monitoring. Today, the Uppsala Monitoring Centre (UMC) in Sweden manages VigiBase, the global computerized repository of Individual Case Safety Reports (ICSRs), which collects post-market safety information submitted by over one hundred and seventy member countries.

In India, drug safety monitoring is anchored by the Pharmacovigilance Programme of India (PvPI), launched in July 2010 by the Ministry of Health and Family Welfare. The Indian Pharmacopoeia Commission (IPC) in Ghaziabad functions as the National Coordinating Centre for PvPI, operating under the regulatory supervision of the Central Drugs Standard Control Organization (CDSCO). Networked Adverse Drug Reaction Monitoring Centres located in medical colleges and tertiary hospitals collect, evaluate, and upload safety reports into the national database. India has also broadened surveillance through the Materiovigilance Programme of India for medical devices and the Haemovigilance Programme for blood transfusions. These systematic monitoring mechanisms protect public health, inform regulatory label changes, and prevent preventable drug-induced patient harm across the nation.

Key Concepts & Self-Assessment20 Key Facts

Review key Pharmacovigilance & Adverse Drug Reaction Monitoring exam facts and rate your mastery to track revision.

Progress: 0/20 Rated 0 Mastered 0 Review Later
#1
The World Health Organization defines pharmacovigilance as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or other drug-related issues.
#2
An Adverse Drug Reaction (ADR) is an appreciably harmful or unpleasant reaction resulting from an intervention related to the use of a medicinal product.
#3
The thalidomide tragedy in 1961, which caused severe phocomelia or limb shortening in over 10,000 newborn babies worldwide, catalyzed modern international pharmacovigilance frameworks.
#4
Frances Kelsey, a reviewer at the United States Food and Drug Administration, famously blocked US commercial approval of thalidomide due to insufficient peripheral neuropathy safety data.
#5
In response to the thalidomide disaster, the US Congress enacted the Kefauver-Harris Drug Amendments of 1962, requiring manufacturers to prove both drug efficacy and safety.
#6
The World Health Organization established the Programme for International Drug Monitoring (PIDM) in 1968 to coordinate global adverse drug reaction surveillance.
#7
The Uppsala Monitoring Centre (UMC), an independent non-profit foundation based in Uppsala, Sweden, manages the technical operations of the WHO PIDM.
#8
VigiBase, maintained by the Uppsala Monitoring Centre, is the unique global repository containing tens of millions of Individual Case Safety Reports from participating nations.
#9
Post-marketing surveillance is categorized as Phase IV clinical research, evaluating real-world safety after pharmaceutical approval across large, diverse patient groups.
#10
The Ministry of Health and Family Welfare initiated the Pharmacovigilance Programme of India (PvPI) in July 2010 to monitor drug safety across Indian healthcare institutions.
#11
The Indian Pharmacopoeia Commission (IPC) in Ghaziabad, Uttar Pradesh, has functioned as the National Coordinating Centre for the PvPI since April 2011.
#12
The Central Drugs Standard Control Organization (CDSCO), led by the Drugs Controller General of India (DCGI), exercises statutory authority over national drug approvals and safety alerts.
#13
India has established hundreds of Adverse Drug Reaction Monitoring Centres (AMCs) across government medical colleges, autonomous institutes, and district hospitals.
#14
The United Kingdom pioneered spontaneous ADR reporting by establishing the Yellow Card Scheme in 1964 following the thalidomide crisis.
#15
In the United States, the Food and Drug Administration maintains the FDA Adverse Event Reporting System (FAERS) and the MedWatch voluntary safety reporting portal.
#16
Materiovigilance Programme of India (MvPI), coordinated through IPC Ghaziabad, systematically monitors adverse events associated with medical devices and implants.
#17
The Haemovigilance Programme of India monitors adverse transfusion reactions and blood product complications, coordinated by the National Institute of Biologicals in Noida.
#18
Causality assessment in pharmacovigilance utilizes standardized clinical algorithms, such as the Naranjo Scale and the WHO-UMC causality assessment system, to determine drug-reaction links.
#19
Under the Drugs and Cosmetics Rules, 1945, pharmaceutical marketing authorization holders in India are legally mandated to submit Periodic Safety Update Reports (PSURs).
#20
In 2017, the CDSCO and PvPI mandated the inclusion of specific box warnings on fixed-dose drug combinations linked to severe cutaneous adverse reactions like Stevens-Johnson syndrome.

Subject Specialist Commentary

Analytical perspective & practical exam advice from the Master10 academic board

Educator's Insight
Pharmacovigilance functions as an active safety net across the entire lifespan of medical products. Controlled clinical trials involve limited sample sizes that cannot detect adverse reactions occurring in fewer than one in ten thousand patients. Systematic post-marketing surveillance, known as Phase IV monitoring, gathers clinical data from diverse patient populations in real-world settings. This vigilant tracking enables regulatory agencies to identify unexpected toxicities, revise safety warnings, and revoke drug approvals when risks outweigh medical benefits.
For competitive exams, candidates must distinguish between pre-approval clinical phases and post-approval Phase IV pharmacovigilance. Remember that the Pharmacovigilance Programme of India is coordinated by the Indian Pharmacopoeia Commission in Ghaziabad, working with the CDSCO headed by the Drugs Controller General of India. Do not confuse the Uppsala Monitoring Centre in Sweden with WHO headquarters in Geneva. For rapid recall during exams, memorize the acronym "ALERT": Adverse reactions Lead to Evidence-based Regulatory Termination.

Related Knowledge Topics to Discover

Looking for more GK practice?

Explore 52,789+ questions across 65 General Knowledge categories.

Open Interactive Search